This is a summary of the European public assessment report (EPAR) for Marixino. It explains how the European Medicines Agency assessed the medicine to recommend its authorisation in the European Union (EU) and its conditions of use. It is not intended to provide practical advice on how to use Marixino. For practical information about using Marixino, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of patients with moderate to severe Alzheimer’s disease.
Therapeutic Area (MeSH)
N/AATC Code
N06DX01
ATC Item
memantine
Pharmacotherapeutic Group
Other anti-dementia drugs
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| memantine hydrochloride | N/A | 美金刚 |
EMA Name
Marixino (previously Maruxa)
Medicine Name
Marixino (previously Maruxa)
Aliases
N/ANo risk management plan link.
